Related Experiment Video
Updated: Aug 14, 2026
11:49
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Immunosuppression-associated lymphoproliferative disorders in rheumatic patients
O W Kamel1, M van de Rijn, M M Hanasono
1Department of Pathology, Stanford University Medical Center, California 94305, USA.
Leukemia & Lymphoma
|February 1, 1995
Summary
Rheumatic disease patients may develop specific lymphomas, similar to those seen in immunocompromised individuals. This suggests that immune system changes from rheumatic disease or its treatments could contribute to lymphoma development.
Area of Science:
- Immunology
- Oncology
- Rheumatology
Background:
- The link between rheumatic diseases and hematolymphoid neoplasms is long-standing.
- Recent findings show rheumatic patients developing lymphoproliferative disorders akin to those in immunocompromised states.
Purpose of the Study:
- To review lymphoproliferative disorders in immunocompromised patients.
- To examine lymphomas in rheumatic patients, focusing on immunosuppression-associated types.
- To explore the role of immune impairment in lymphoma development within this cohort.
Main Methods:
- Literature review of lymphoproliferative disorders in immunocompromised states.
- Review of recent reports on lymphomas in rheumatic patients.
- Analysis of shared characteristics between lymphomas in immunosuppressed and rheumatic patients.
Main Results:
- Lymphoid neoplasms in immunosuppressed patients often feature Epstein-Barr virus (EBV) in neoplastic cells.
- Rheumatic patients can develop lymphomas with features similar to those in immunosuppressed individuals.
- Immune system impairment, potentially from rheumatic disease or its treatment, is implicated.
Conclusions:
- Immune system impairment secondary to rheumatic disease or its treatment may contribute to lymphoma development.
- Further research is needed to differentiate the roles of the disease itself versus its therapy in lymphoma etiology.
- Understanding these associations is crucial for managing rheumatic disease patients at risk for lymphoid malignancies.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...